Advanced search
Publication Cover
Substance Abuse Volume 33, 2012 - Issue 1: Pharmacotherapies for Opioid Dependence in Criminal Justice Populations
Journal homepage
502
Views
44
CrossRef citations to date
0
Altmetric
Original Articles

A Multisite Pilot Study of Extended-Release Injectable Naltrexone Treatment for Previously Opioid-Dependent Parolees and Probationers

Donna M. Coviello PhD University of Pennsylvania, Philadelphia, Pennsylvania, USA
,
James W. Cornish MD University of Pennsylvania, Philadelphia, Pennsylvania, USA; Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA
,
Kevin G. Lynch PhD University of Pennsylvania, Philadelphia, Pennsylvania, USA
,
Tamara Y. Boney MS University of Pennsylvania, Philadelphia, Pennsylvania, USA
,
Cynthia A. Clark MSN, CRNP, APRN, BC University of Pennsylvania, Philadelphia, Pennsylvania, USA
,
Joshua D. Lee MD, MSc New York University/Bellevue Hospital, New York, New York, USA
,
Peter D. Friedmann MD, MPH Veterans Affairs Medical Center, Rhode Island Hospital, Providence, Rhode Island, USA; Brown University, Providence, Rhode Island, USA
,
Edward V. Nunes MD Columbia University, New York, New York, USA
,
Timothy W. Kinlock PhD Friends Research Institute, Baltimore, Maryland, USA; University of Baltimore, Baltimore, Maryland, USA
,
Michael S. Gordon DPA Friends Research Institute, Baltimore, Maryland, USA
,
Robert P. Schwartz MD Friends Research Institute, Baltimore, Maryland, USA
,
Elie S. Nuwayser PhD Biotek, Inc., Woburn, Massachusetts, USA
&
Charles P. O’Brien MD, PhD University of Pennsylvania, Philadelphia, Pennsylvania, USA; Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA
 show all
Pages 48-59 | Published online: 20 Jan 2012
 
Sample our Behavioral Sciences journals, sign in here to start your access, latest two full volumes FREE to you for 14 days

ABSTRACT

A feasibility study was conducted to pilot test the ability of 5 sites to recruit, treat, and retain opioid-dependent offenders in a trial of extended-release injectable naltrexone (XR-NTX). The participants, 61 previously opioid-dependent individuals under legal supervision in the community, received up to 6 monthly injections of Depotrex brand naltrexone and completed a 6-month follow-up interview. Six-month outcomes showed that those who completed treatment had significantly fewer opioid-positive urines and were less likely to have been incarcerated than those who had not completed treatment. The findings indicate that XR-NTX holds promise as a feasible, effective treatment option for opioid-dependent offenders.

Acknowledgments

The study was supported by grants from the National Institute on Drug Abuse (R01-DA-012268-05) and the Dana foundation.

Log in via your institution

Access through your institution

Log in to Taylor & Francis Online

Restore content access

Restore content access for purchases made as guest
There are no offers available at the current time.

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.